When considering the benefit (pCR) and risk (SAE) together, T-DM1PC and T-DM1 were identified as the optimal neoadjuvant therapy for early-stage HER2+ve breast cancer given the greater chance of achieving pCR and the low risk of SAE. Here, ERBB2 is linked to breast carcinoma.